Auris Medical Holding AG (NASDAQ:EARS) dropped NaN during trading on Tuesday . The stock traded as low as $0.70 and last traded at $0.00. Approximately 524,700 shares traded hands during mid-day trading, an increase of Infinity from the average daily volume of 0 shares.

EARS has been the subject of several recent research reports. ValuEngine cut Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Roth Capital reissued a “buy” rating and issued a $5.00 price target on shares of Auris Medical Holding AG in a research note on Saturday, July 1st. Finally, Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Auris Medical Holding AG has a consensus rating of “Hold” and a consensus target price of $3.25.

The stock’s market capitalization is $34.93 million. The company’s 50 day moving average is $0.71 and its 200 day moving average is $0.75.

Auris Medical Holding AG (NASDAQ:EARS) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.09. Equities analysts expect that Auris Medical Holding AG will post ($0.63) earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in EARS. Sabby Management LLC acquired a new stake in Auris Medical Holding AG in the 1st quarter valued at approximately $133,000. Perceptive Advisors LLC acquired a new stake in Auris Medical Holding AG in the 1st quarter valued at approximately $368,000. UBS Oconnor LLC acquired a new stake in Auris Medical Holding AG in the 1st quarter valued at approximately $909,000. Finally, Virtu KCG Holdings LLC acquired a new stake in Auris Medical Holding AG in the 2nd quarter valued at approximately $101,000. 28.38% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/28/auris-medical-holding-ag-ears-shares-down-nan.html.

About Auris Medical Holding AG

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Stock Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related stocks with our FREE daily email newsletter.